Abstract
Purpose :
Proliferative Vitreoretinopathy (PVR) is a major complication of rhegmatogenous retinal detachments (RRD), and it is characterized by growth and contraction of cellular membranes within the vitreous cavity and on both sides of the retina. PVR is the most common cause for failure of RRD repair. The purpose of this study is to assess the risk for development of PVR after RD repair in a patient’s second eye if the patient had initially developed PVR after RD repair in the first eye.
Methods :
A retrospective cohort study was performed using the de-identified Vestrum Health Database. Patients who underwent unilateral RRD repair between January 2015 and August 2022 who had at least 3 months of follow-up were included in the study. Eyes with proliferative diabetic retinopathy were excluded. Among these patients, PVR rates were identified within 180 days following unilateral RRD repair. Within this cohort, patients who presented with or developed a RRD in the second eye were identified, and second eye PVR rates were then assessed.
Results :
A total of 44,441 patients who initially had a unilateral RRD repair were identified. Mean Age was 60 years old and 62% were male. This cohort can be stratified into 4,649 patients who subsequently developed PVR after RRD repair and 39,792 patients who did not develop PVR after RRD repair. Of the 4,649 patients, 289 presented with or developed a RRD in the contralateral eye. Of these 289 patients, 11 (4%) developed PVR in the contralateral eye. Of the 39,792 patients who did not develop PVR after the first eye RRD repair, 3,706 presented with or developed a RRD in the contralateral eye. Of these 3,706 patients, 128 (3%) developed PVR in the contralateral eye. The relative risk (RR) of PVR development in the contralateral eye if the first eye had developed PVR is 1.10.
Conclusions :
Based on our data set, our relative risk of 1.10 implies that there may be a slightly higher risk of PVR in a patient’s second eye if the first eye developed PVR. Our findings have implications regarding the need for prophylactic treatment at the time or after RRD repair to prevent PVR. Further investigation using this dataset is ongoing.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.